AbbVie Inc. and the French regulatory agency ANSM are responding to coronavirus-related shortages of the company’s HIV treatment Kaletra (lopinavir + ritonavir) in France by allowing the supply of other versions of the product that were destined for non-EU markets.
Stocks of the combination drug have been under pressure because some doctors have been giving it to patients with COVID-19 infection. Last week ANSM advised general practitioners not to prescribe Kaletra or Sanofi’s Plaquenil (hydroxychloroquine) for these patients because shortages were being seen in community pharmacies, and a government decree of 26 March said that any COVID-19-related use must be restricted to hospitals and clinical trials
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?